1. Home
  2. EARN vs CRBU Comparison

EARN vs CRBU Comparison

Compare EARN & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

EARN

Ellington Residential Mortgage REIT of Beneficial Interest

HOLD

Current Price

$5.32

Market Cap

189.7M

Sector

Real Estate

ML Signal

HOLD

Logo Caribou Biosciences Inc.

CRBU

Caribou Biosciences Inc.

HOLD

Current Price

$1.67

Market Cap

203.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EARN
CRBU
Founded
2012
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Medicinal Chemicals and Botanical Products
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
189.7M
203.9M
IPO Year
2013
2021

Fundamental Metrics

Financial Performance
Metric
EARN
CRBU
Price
$5.32
$1.67
Analyst Decision
Buy
Strong Buy
Analyst Count
2
3
Target Price
$5.88
$9.33
AVG Volume (30 Days)
323.8K
997.8K
Earning Date
02-20-2026
11-12-2025
Dividend Yield
18.18%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$35,893,000.00
$9,295,000.00
Revenue This Year
$8.43
N/A
Revenue Next Year
$17.28
$4.96
P/E Ratio
N/A
N/A
Revenue Growth
43.30
N/A
52 Week Low
$4.33
$0.66
52 Week High
$6.86
$3.54

Technical Indicators

Market Signals
Indicator
EARN
CRBU
Relative Strength Index (RSI) 52.63 36.53
Support Level $5.10 $1.82
Resistance Level $5.20 $1.75
Average True Range (ATR) 0.10 0.10
MACD -0.00 -0.01
Stochastic Oscillator 60.18 14.49

Price Performance

Historical Comparison
EARN
CRBU

About EARN Ellington Residential Mortgage REIT of Beneficial Interest

Ellington Credit Co is focused on corporate collateralized loan obligations (CLOs). It focuses on acquiring, investing in, and managing secondary CLO mezzanine debt and equity tranches. The company relies on risk management, including disciplined liquidity management and selective use of credit hedges, to preserve book value during times. The company primary investment objectives are to generate attractive current yields and risk-adjusted total returns for shareholders. It invest in multiple parts of the CLO capital structure, principally mezzanine debt and equity tranches. Rather than focusing only on short-term current yield, it select investments that it believe will provide a strong total return to drive a sustainable earnings stream over a long-term horizon.

About CRBU Caribou Biosciences Inc.

Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.

Share on Social Networks: